Audited Financial Results and recommendation of final dividend for financial year 2025-26
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Smallcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neuland Laboratories reported strong FY2025-26 results with consolidated revenue growing 37% to Rs 2,023 crore from Rs 1,477 crore. Profit after tax jumped 40% to Rs 364 crore from Rs 260 crore, driven by robust growth across all geographies — Europe revenue up 57%, USA/North America up 69%. The Board recommended a final dividend of Rs 34 per share (340%). An exceptional gain of Rs 76.4 crore from sale of investment property in Hyderabad was recorded. Statutory auditors MSKA & Associates issued an unmodified opinion with no concerns. The company also announced a Rs 143.4 crore capacity expansion at its Bonthapally Unit 1 (120.5 KL addition in 12-18 months) to meet growing customer demand. Finance costs nearly tripled to Rs 23.9 crore due to increased borrowings.
Strong operational performance with 40% PAT growth and positive dividend signal shareholder-friendly policy. The capacity expansion investment indicates management confidence in sustained demand growth. Unmodified auditor opinion with no going concern issues is reassuring.